DV
Dividend Vision

MPLT — MapLight Therapeutics, Inc. Common Stock

MapLight Therapeutics, Inc. Common Stock (MPLT)

Total return is -35.9% over the past 0.8 years, 50.1 points behind SPY at 14.2%.

MapLight Therapeutics is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders including schizophrenia, Alzheimer's disease psychosis, autism spectrum disorder, and Parkinson's disease, with a platform technology focused on identifying and targeting disease-linked neural circuits. The company does not currently distribute dividends. MapLight appeals to investors with high risk tolerance interested in early-stage biotech development rather than income-focused strategies.

MPLT key facts

Asset type
Stock
Asset class
Equity
Inception date
10/27/2025
Last close
$11.75
Market cap
$1,631,990,912
Average volume
451800.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.41